Tome Biosciences to Present Data on Programmable Genomic Integration Technologies at ASGCT
23 avr. 2024 08h00 HE
|
Tome Biosciences
Tome to present data at ASGCT.
Tome Biosciences Announces US Patent Issued for Integrase-Mediated Programmable Genomic Integration
09 avr. 2024 08h08 HE
|
Tome Biosciences
Tome granted US patent for programmable genomic integration.
Tome Biosciences Forms Science and Technology Advisory Committee
04 mars 2024 08h00 HE
|
Tome Biosciences
Tome forms Science and Technology Advisory Committee.
Tome Biosciences Appoints Industry Veteran Daniel Curran, MD, to its Board of Directors
30 janv. 2024 08h00 HE
|
Tome Biosciences
Tome Biosciences appoints Daniel Curran, MD, to its Board of Directors.
Tome Biosciences Acquires Replace Therapeutics
02 janv. 2024 09h00 HE
|
Tome Biosciences
Tome acquires Replace Therapeutics.
Tome Biosciences Launches with Over $200 Million in Funding to Advance Programmable Genomic Integration Platform
12 déc. 2023 07h57 HE
|
Tome Biosciences
Tome Biosciences launches with over $200 million in funding to advance programmable genomic integration (PGI).